INVEGA HAFYERA

Peak

paliperidone palmitate

NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASEPriority Review
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

[see ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, its efficacy in the treatment of schizophrenia could be mediated through a combination of central dopamine D 2 and serotonin 5HT 2A receptor antagonism.

Clinical Trials (5)

NCT04940039Phase 4Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Started Jul 2021
93 enrolled
Schizophrenia
NCT04072575Phase 3Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Started Sep 2019
178 enrolled
Schizophrenia
NCT03809325N/ACompleted

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Started Nov 2018
225 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03666715N/ACompleted

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

Started Aug 2018
55 enrolled
Schizophrenia

Loss of Exclusivity

LOE Date
Nov 24, 2041
191 months away
Patent Expiry
Nov 24, 2041

Patent Records (5)

Patent #ExpiryTypeUse Code
10143693
Apr 5, 2036
U-2457
11304951
May 7, 2041
U-3349
11324751
May 7, 2041
U-3359
12208100
May 7, 2041
U-3359
11666697
Nov 24, 2041
U-3626